A key figure in navigating NYPC through the COVID crisis, former CFO Jonathan Weinbach will steer the innovative proton radiation facility into a new era, building upon the rapid growth in its first 18 months of operation
Operated by a consortium of NYC providers including MSK, Montefiore and Mt. Sinai, NYPC has quickly become one of the busiest proton centers in the United States
New York, January 12, 2021 — Today the New York Proton Center (NYPC), the New York City-based proton therapy facility operated in partnership with Memorial Sloan Kettering Cancer Center, Montefiore Health System and Mount Sinai Health System, announced that longtime health care executive Jonathan Weinbach has been appointed CEO.
As the center’s former CFO and an integral part of the center’s development since its inception over ten years ago, Weinbach brings extensive experience and tremendous market knowledge to the position. NYPC’s former CEO, Allan Freeman, will transition to a special advisory role after providing essential leadership through the institution’s successful launch and robust initial growth period.
“This is a pivotal moment for cancer providers across the country. COVID has forced us to be nimble in confronting major challenges to care delivery. I’m proud we remained safely open for our patients throughout 2020, and I am confident we are positioned for continued growth as we meet the demand of New Yorkers and those around the world seeking the best radiation treatment available to them,” said Jonathan Weinbach, incoming Chief Executive Officer of the New York Proton Center. “Moving forward, and with the continued support of our prestigious clinical partners, my focus will be on advancing our capacity as a center of clinical excellence and as a hub for innovative research that transforms the treatment paradigm for the next generation of patients.”
Despite the challenges of the COVID pandemic, today NYPC is treating nearly 100 patients per day—an unprecedented volume at this stage in its development compared to the nearly 40 other proton facilities across the United States. Since opening for treatment in August 2019, the New York Proton Center has ramped up its capacity at a rapid pace, and currently treats the most complex and diverse caseload of any center of its kind. That is due in no small part to the collaboration of its renowned institutional partners, all based in close proximity to NYPC.
“Jon’s strong commitment to the Center, energetic leadership and keen intuition for what drives growth and innovation has already been a critical part of its success and will ensure the New York Proton Center becomes a case study in proton therapy’s potential to become a new standard of radiation care,” said Donald Scanlon, Chairman of the Board of the New York Proton Center. “After conducting an extensive nationwide search of leaders in the field, we believe more firmly than ever that he is the right person to carry on the legacy of Allan’s many years of great leadership.”
Prior to serving as the NYPC’s CFO, Weinbach led several divisions at 21st Century Oncology, the largest private provider of radiation therapy services in the United States. He is a member of the American College of Healthcare Executives and a representative on several committees of the National Association of Proton Therapy.
For additional information, please visit www.nyproton.com.
About the New York Proton Center
The New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers—Memorial Sloan Kettering Cancer Center, Montefiore Health System, Mount Sinai Health System, and ProHEALTH as manager—the New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy.